Chennai, India

Kamaraj Mani

This inventor holds 1 USPTO granted patent. Top assignee: Orchid Chemicals & Pharmaceuticals Limited. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kamaraj Mani. Retrieved from https://idiyas.com/inventor/kamaraj-mani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kamaraj Mani: Innovator in Therapeutic Compounds

Introduction

Kamaraj Mani is a notable inventor based in Chennai, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Kamaraj Mani holds a patent for histone deacetylase inhibitors. The patent describes novel, stilbene-like compounds that can inhibit HDACs. These compounds are useful as therapeutic agents for various diseases, including malignant tumors, autoimmune diseases, skin diseases, infections, and inflammation.

Career Highlights

Kamaraj Mani is associated with Orchid Chemicals & Pharmaceuticals Limited, where he applies his expertise in drug development. His work focuses on creating innovative solutions to combat serious health issues.

Collaborations

Some of his coworkers include Sridharan Rajagopal and Virendra Kachhadia, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Kamaraj Mani's work in developing histone deacetylase inhibitors showcases his commitment to advancing therapeutic options in medicine. His contributions are vital in addressing complex health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…